2.300USDMkt Cap: 4.93M USDP/E: —Last update: 2026-05-21
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap4.93M USD
Enterprise Value-3.84M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-7.98M USD
Revenue/Share—
Last Price2.300 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.92
PEG—
EV/EBITDA0.49
EV/Revenue—
P/S—
P/B0.48
EPS (TTM)-4.89
EPS (Forward)-2.49
52W Range
2.10069% of range2.390
52W High2.390 USD
52W Low2.100 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-151.18%
ROA-119.54%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.49M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-76.43%
Net Debt-5.88M USD
Net Debt/EBITDA0.75
Balance Sheet
Debt/Equity—
Current Ratio4.42
Quick Ratio4.21
Book Value/Sh4.749 USD
Cash/Share4.119 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateFeb 6, 2026
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)25.00 USD
Target Range8.000 USD – 42.00 USD
# Analysts2
Ownership
Shares Out.2.14M
Float1.28M
Insiders7.99%
Institutions9.89%
Short Interest
Short Ratio0.6d
Short % Float3.46%
Short % Out.3.43%
Shares Short49.01K
Short (prev mo.)79.61K
Technical
SMA 501.669 (+37.8%)
SMA 2005.737 (-59.9%)
Beta1.27
S&P 52W Chg28.31%
Avg Vol (30d)172.05K
Avg Vol (10d)309.53K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—